Background: Atopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic diseases in dogs. Considering its multifactorial nature, AD can be a challenging disease to manage, and the therapeutic strategy must often be multimodal. In recent years, research has been moving toward the use of natural products which have beneficial effects on inflammation and itching, and no side effects. Cannabinoid receptors have been demonstrated to be expressed in healthy and diseased skin; therefore, one of the potential alternative therapeutic targets for investigating AD is the endocannabinoid system (ECS). Objective: To immunohistochemically investigate the expression of the cannabinoid receptor type 2 (CB2R), and the cannabinoid-re...
Endocannabinoids (ECs) are involved in immunomodulation, neuroprotection and control of inflammation...
Atopic dermatitis in humans and dogs is a chronic relapsing allergic skin disease. Dogs show a spont...
BACKGROUND: Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compound...
Background: Atopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic dis...
It is commonly accepted that some form of skin barrier dysfunction is present in canine atopic derma...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
OBJECTIVE: To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid...
Atopic dermatitis (AD) is one of the most frequent skin disease of dogs. Although its pathogenesis i...
IntroductionDermatological consultations represent a great part of the small animal medical clinic r...
Cannabinoid receptors (CB1 and CB2) belong to endocannabinoid system (ECS), which is also composed f...
Growing evidence indicates cannabinoid receptors as potential therapeutic targets for chronic pain. ...
Abstract Background The endocannabinoid system (ECS) is composed of cannabinoid receptors type 1 (CB...
Background: Cannabinoid receptors and peroxisome proliferator-activated receptor-alpha (PPAR-α) are ...
Endocannabinoids (ECs) are involved in immunomodulation, neuroprotection and control of inflammation...
Atopic dermatitis in humans and dogs is a chronic relapsing allergic skin disease. Dogs show a spont...
BACKGROUND: Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compound...
Background: Atopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic dis...
It is commonly accepted that some form of skin barrier dysfunction is present in canine atopic derma...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
BackgroundAtopic dermatitis (AD) is one of the most common cutaneous inflammatory and pruritic disea...
OBJECTIVE: To determine the distribution of cannabinoid receptor type 1 (CB1) and cannabinoid...
Atopic dermatitis (AD) is one of the most frequent skin disease of dogs. Although its pathogenesis i...
IntroductionDermatological consultations represent a great part of the small animal medical clinic r...
Cannabinoid receptors (CB1 and CB2) belong to endocannabinoid system (ECS), which is also composed f...
Growing evidence indicates cannabinoid receptors as potential therapeutic targets for chronic pain. ...
Abstract Background The endocannabinoid system (ECS) is composed of cannabinoid receptors type 1 (CB...
Background: Cannabinoid receptors and peroxisome proliferator-activated receptor-alpha (PPAR-α) are ...
Endocannabinoids (ECs) are involved in immunomodulation, neuroprotection and control of inflammation...
Atopic dermatitis in humans and dogs is a chronic relapsing allergic skin disease. Dogs show a spont...
BACKGROUND: Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compound...